Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $170.67 Average Target Price from Brokerages

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have received an average recommendation of “Buy” from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $170.67.

Several analysts recently weighed in on TENX shares. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday. Leerink Partners began coverage on Tenax Therapeutics in a research report on Thursday. They set an “outperform” rating and a $16.00 price target on the stock. StockNews.com assumed coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating on the stock. William Blair assumed coverage on Tenax Therapeutics in a report on Monday, September 30th. They issued an “outperform” rating for the company. Finally, Guggenheim started coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price target for the company.

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock opened at $4.75 on Friday. The firm has a fifty day moving average price of $3.79 and a 200 day moving average price of $3.58. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.99) by $0.16. As a group, equities analysts expect that Tenax Therapeutics will post -6.75 EPS for the current year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.